Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Oral vs SC Methotrexate (VIBEX) in RA
NCT01618968Phase 2Completed
- Sponsor
- Antares Pharma, Inc.
- Start
- May 2012
- Primary completion
- Aug 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methotrexate in rheumatoid arthritis (RA) (4 arms), sponsored by Antares Pharma, Inc. Primary endpoints: Dose-Normalized AUC[0-Inf] for MTX at 24 hours, Dose-Normalized AUC[0-24] for MTX at 24 hours and 1 more. Started May 2012; status: completed.
02
Drugs
methotrexate
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01618968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01618968.